#Israel #AstraZeneca #Compugen #Holon #Gilead

Compugen Reports Fourth Quarter and Full Year 2025 Results

Compugen Ltd. has recently released its financial results for the fourth quarter and the entire year of 2025, showcasing substantial progress and optimization of its operations in the competitive field of cancer immunotherapy. The company has strengthened its financial situation through a notable non-dilutive transaction with AstraZeneca, allowing it to monetize a portion of its royalties from rilvegostomig, thereby extending its cash runway into 2029.

Financial Highlights

As of December 31, 2025, Compugen holds approximately $145.6 million in cash and equivalents. The cash position is bolstered by a significant upfront payment of $65 million from AstraZeneca linked to the royalty monetization deal. Additionally, the company anticipates future milestone payments, which suggest a promising financial outlook going forward.

Compugen's revenues for the fourth quarter stand at approximately $67.3 million, a stark increase compared to $1.5 million in the same period last year. For the full year of 2025, total revenue reached around $72.8 million, sharply contrasted with $27.9 million recorded in 2024. This remarkable growth is attributed to the recent agreements with AstraZeneca and Gilead, along with the successful advancement of various clinical trials.

Strategic Partnerships and Clinical Trials

In his remarks, Dr. Eran Ophir, President and CEO of Compugen, emphasized the significant progress made in 2025, particularly the cash runway extension and enhanced collaborations. Dr. Ophir shared, "This strategic transaction not only reinforces our cash position but also retains the potential for long-term value from a multi-billion-dollar asset being advanced by AstraZeneca across ten Phase 3 clinical trials targeting several cancers, including lung and gastrointestinal."

The leadership transition within the company has also been notable, with Dr. Anat Cohen-Dayag stepping into the role of Executive Chair and Dr. Ophir taking charge as President and CEO. This shift aims to provide renewed focus and energy as the company continues its research and clinical efforts.

Compugen has initiated significant studies, notably trials for its wholly-owned drug candidate, COM701 for ovarian cancer and GS-0321, a collaborative project with Gilead. The company is expanding its global clinical trial presence, which now includes sites in the U.S., Israel, and France.

The anticipated interim analysis for the MAIA-ovarian trial is expected in the first quarter of 2027, with preliminary data from both COM701 and GS-0321 presented at key medical conferences in 2025.

Future Outlook

Looking ahead into 2026, Compugen is poised for growth, thanks to a solid balance sheet, a validated AI/ML-driven discovery platform, and a robust clinical pipeline accentuated by promising existing partnerships. Dr. Ophir remains optimistic about the direction the company is heading, expressing pride in the team's endeavors and eagerness for the future.

The company will further discuss its financials and strategic goals in a live conference call, reinforcing its commitment to transparency with stakeholders.

In summary, Compugen Ltd. has demonstrated remarkable resilience and forward momentum in 2025, reinforcing its reputation as a key player in the realm of cancer therapies. The focus on innovation, strategic alliances, and clinical execution positions the company well for future success.